Literature DB >> 33480609

Telemedicine in the Coronavirus Disease 2019 Pandemic: A Pediatric Rehabilitation Perspective.

Yuxi Chen1, Dona Rani Kathirithamby, Jinpu Li, Coral Candelario-Velazquez, Andrew Bloomfield, Anne Felicia Ambrose.   

Abstract

ABSTRACT: In the spring of 2020, coronavirus disease 2019 evolved into a worldwide pandemic, forcing traditional face-to-face healthcare to a standstill. Telemedicine was quickly adopted as a major tool for pediatric rehabilitation services. This article describes the national legislative response of the United States to the coronavirus disease 2019 pandemic and the opportunities and challenges of implementing telemedicine in pediatric rehabilitation outpatient settings, consultations, as well as physician and patient education. The feasibility of performing a remote pediatric musculoskeletal and neurological tele-evaluation is also discussed. Although challenges exist, telemedicine has demonstrated its potential and has proven to be a practical system. Future developments in technology and accessibility, in addition to support from government and third-party payers, have the potential to make telemedicine an effective and vital platform in a coordinated healthcare system.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33480609     DOI: 10.1097/PHM.0000000000001698

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  2 in total

1.  Impact of COVID-19 on outpatient appointments in children and young people in England: an observational study.

Authors:  Alex Bottle; Francesca K Neale; Kimberley A Foley; Russell M Viner; Simon Kenny; Paul Aylin; Sonia Saxena; Dougal S Hargreaves
Journal:  BMJ Open       Date:  2022-08-08       Impact factor: 3.006

2.  Ethical responsibilities of European children's teams facing the resurgent COVID-19 pandemic.

Authors:  Anna Zanin; Enrico Furlan; Marek Migdal; Joe Brierley
Journal:  Eur J Pediatr       Date:  2021-07-09       Impact factor: 3.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.